IDEXX Laboratories, Inc. $IDXX Shares Sold by Hantz Financial Services Inc.

Hantz Financial Services Inc. lowered its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 7.5% during the 4th quarter, Holdings Channel reports. The fund owned 26,617 shares of the company’s stock after selling 2,148 shares during the period. Hantz Financial Services Inc.’s holdings in IDEXX Laboratories were worth $18,007,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also made changes to their positions in IDXX. Beacon Investment Advisory Services Inc. lifted its holdings in shares of IDEXX Laboratories by 11.9% during the fourth quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock valued at $42,588,000 after purchasing an additional 6,710 shares during the last quarter. Nordea Investment Management AB boosted its stake in IDEXX Laboratories by 114.1% during the fourth quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock worth $11,283,000 after buying an additional 8,845 shares in the last quarter. New York State Common Retirement Fund grew its stake in shares of IDEXX Laboratories by 6.8% in the 3rd quarter. New York State Common Retirement Fund now owns 60,225 shares of the company’s stock valued at $38,477,000 after purchasing an additional 3,820 shares during the period. Mediolanum International Funds Ltd increased its position in shares of IDEXX Laboratories by 14.5% during the 3rd quarter. Mediolanum International Funds Ltd now owns 38,761 shares of the company’s stock worth $24,441,000 after purchasing an additional 4,909 shares in the last quarter. Finally, Procyon Advisors LLC bought a new position in IDEXX Laboratories during the 4th quarter valued at about $1,966,000. 87.84% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CEO Jonathan Jay Mazelsky sold 23,326 shares of the firm’s stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the sale, the chief executive officer directly owned 83,606 shares in the company, valued at $54,975,125.30. This trade represents a 21.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Nimrata Hunt sold 1,758 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total value of $1,115,574.06. Following the completion of the sale, the executive vice president owned 18,141 shares in the company, valued at approximately $11,511,734.37. This trade represents a 8.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 27,777 shares of company stock valued at $18,235,113 over the last 90 days. Corporate insiders own 0.79% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $559.37 on Monday. IDEXX Laboratories, Inc. has a 52 week low of $496.61 and a 52 week high of $769.98. The firm has a fifty day moving average of $566.51 and a two-hundred day moving average of $642.13. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. The stock has a market capitalization of $44.12 billion, a price-to-earnings ratio of 41.19, a PEG ratio of 3.25 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.41 by $0.06. The company had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period in the previous year, the company earned $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, equities research analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on IDXX shares. Stifel Nicolaus decreased their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. UBS Group decreased their price target on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Citigroup assumed coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target for the company. BTIG Research reduced their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research note on Tuesday, February 3rd. Finally, Piper Sandler decreased their target price on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. Seven investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.